July 12 Watson Pharmaceuticals Inc said
the Federal Trade Commission requested additional information
regarding Watson's proposed acquisition of Swiss generic drug
firm Actavis Group.
The request by the FTC, which looks into potential deals to
see if there is any possibility of unfair competition that may
result from the deal, will extend a waiting period on the firms
until 30 days after they have complied with the request.
Watson had said in April that it would buy Actavis for at
least 4.25 billion euros ($5.60 billion), in a deal that would
bolster its place among one of the world's biggest generic drug
firms and expand its international presence.
The company said it intends to cooperate fully with the
FTC's review and continues to expect the deal to close in the
fourth quarter of 2012.
Watson shares closed at $74.70 on the New York Stock
Exchange on Wednesday.